{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-013408","form_type":"8-K","ticker":"ZIVO","cik":"0001101026","company_name":"Zivo Bioscience, Inc.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.220899+00:00","generated_at":"2026-06-09T07:52:29.342994+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zivo Bioscience effects 1-for-6 reverse stock split to regain Nasdaq compliance","bullets":["1-for-6 reverse split effective 5:00 p.m. ET Oct 26, 2023; trading split-adjusted Oct 27.","Authorized shares reduced from 150M to 25M; par value $0.001 unchanged.","No fractional shares issued; cash in lieu based on Oct 26 closing price.","Proportional adjustments to warrants, stock options, and equity plan shares.","Reverse split intended to meet Nasdaq continued listing requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-013408","json":"https://secwatch.observer/filing/0001654954-23-013408.json","markdown":"https://secwatch.observer/filing/0001654954-23-013408.md","text":"https://secwatch.observer/filing/0001654954-23-013408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423013408/0001654954-23-013408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423013408/zivo_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T07:52:29.342994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"862b6deeff5bb92c544609f80a6ad6b3238abe97","claim":"Zivo Bioscience, Inc.: Amended articles to effect a 1-for-6 reverse stock split and reduce authorized common shares from 150,000,000 to 25,000,000 (effective 2023-10-26).","evidence_excerpt":"On October 24, 2023, Zivo Bioscience, Inc. (the “Company”) filed a certificate of amendment to its articles of incorporation with the Secretary of State of the State of Nevada (the “Certificate of Amendment”) to (i) effectuate a reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock and treasury shares on a 1-for-6 basis and (ii) decrease the number of total authorized shares of Common Stock of the Company from 150,000,000 to 25,000,000 shares.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423013408/0001654954-23-013408-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-10-26"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}